Bioventus completed the merger with Misonix in a $518m deal.

Bioventus, a global provider of active orthopaedic healing, providing clinically proven and cost-effective therapies, completed the merger with Misonix, a medical devices company, in a $518m deal. Misonix stockholders own an approximately 25% stake in the combined company, and Bioventus stockholders own an approximately 75% stake. “The proposed combination of Misonix and Bioventus provides Misonix shareholders with substantial immediate and long-term value through a tax-efficient structure and the opportunity to participate in the significant upside potential of the combined organization. Together with Bioventus, we are creating a leading, global restorative medicine and orthopedics company with a comprehensive and best-in-class suite of products and procedural solutions that improve patient outcomes and which are well supported and strategically positioned to grow share across their addressable markets," Stavros Vizirgianakis, Misonix President and CEO.